Answers are grounded in this paper and cite their sources.
Severe fever with thrombocytopenia syndrome (SFTS) associated pulmonary aspergillosis (SAPA) is one of the most serious complications and is strongly associated with high mortality. This study aimed to evaluate the efficacy of voriconazole (VRZ) prophylaxis against SAPA. SFTS patients were stratified into the following groups for comparative analysis: (i) SAPA versus non-SAPA groups; (ii) nonprevention versus prevention groups; (iii) control high-risk (CHR) versus prophylactic high-risk (PHR) groups. The clinical burden of SAPA was assessed by comparing clinical characteristics between SAPA and non-SAPA patients. The efficacy of VRZ prophylaxis was evaluated by comparing SAPA incidence, ICU admission rates, and mortality between nonprevention and prevention groups, as well as between CHR and PHR groups. Among 96 SFTS patients, 35 (36.5%) developed SAPA. The SAPA group exhibited significantly longer mean hospitalization (16.5 ± 12.1 days vs. 8.0 ± 3.1 days; p < 0.001), higher ICU admission rates (40.0% vs. 3.3%; p < 0.001), and higher mortality (34.3% vs. 3.3%; p < 0.001) than the non-SAPA group. Prophylactic VRZ significantly reduced SAPA incidence in both the prevention group (29.0% vs. nonprovention group: 50%; p = 0.041) and the PHR group (47.1% vs. CHR group: 82.4%; p = 0.016). Similarly, ICU admission and mortality rates were markedly lower in the prevention group (4.8% and 8.1%, respectively) versus the nonprovention group (38.2% and 26.5%, respectively), and in the PHR group (5.9% and 11.8%, respectively) versus the CHR group (58.8% and 35.3%, respectively). Prophylactic VRZ significantly reduced SAPA incidence, ICU admissions, and mortality, with no serious adverse events observed.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: